WHO releases list of bacteria that pose greatest threat to humankind

pharmafile | February 28, 2017 | News story | Research and Development WHO, antibiotic resistance 

The World Health Organisation (WHO) has published a list of the 12 bacteria that are thought to present the largest threat to humankind moving into the future. The particular bacteria that appear on the list are identified as being dangerous due to their ability, or increasing ability, to resist current antibiotic.

The list can be viewed as a call to action for the world to address the increasing threat of antibiotic resistance: “This list is a new tool to ensure R&D responds to urgent public health needs,” says Dr Marie-Paule Kieny, WHO’s Assistant Director-General for Health Systems and Innovation. “Antibiotic resistance is growing, and we are fast running out of treatment options. If we leave it to market forces alone, the new antibiotics we most urgently need are not going to be developed in time.”

The reference to ‘leaving it to market forces’ can be understood as an indirect reference to the pharmaceutical industry. At the moment, the major spending done on R&D is done by the pharmaceutical industry in the quest for the next blockbuster drug. However, in the case of antibiotic resistance, there isn’t the same profit to be made.

If any drug were to be developed, it would be used as a one-time or short-duration treatment that would not guarantee a pharmaceutical company long-term profits. The pharmaceutical industry makes it money primarily on those conditions that are chronic and treatments that are absolutely effective have a short shelf life – as Gilead has found with its Hepatitis C treatment.

Instead of being a call to the pharmaceutical industry, WHO has timed the release of the list just before the G20 meeting – where antibiotic resistance, and the threat it poses to human health, is predicted to be on the agenda. It may then be public-sector researchers that will be relied upon to take the lead unless governments can find ways to incentivise the private-sector to see the worth in this global health challenge.

The full list, as arranged by WHO:

Critical priority:

Acinetobacter baumannii, carbapenem-resistant

Pseudomonas aeruginosa, carbapenem-resistant

Enterobacteriaceae, carbapenem-resistant, ESBL-producing

High priority:

Enterococcus faecium, vancomycin-resistant

Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant

Helicobacter pylori, clarithromycin-resistant

Campylobacter spp., fluoroquinolone-resistant

Salmonellae, fluoroquinolone-resistant

Neisseria gonorrhoeae, cephalosporin-resistant, fluoroquinolone-resistant

Medium priority:

Streptococcus pneumoniae, penicillin-non-susceptible

Haemophilus influenzae, ampicillin-resistant

Shigella spp., fluoroquinolone-resistant

Ben Hargreaves

Related Content

Scientists use AI to find new antibiotic to fight superbug

Scientists at McMaster University and the Massachusetts Institute of Technology (MIT) have utilised artificial intelligence …


Moderna to supply up to 500 million COVID-19 vaccines to COVAX

Moderna have announced a supply agreement with Gavi, the Vaccine Alliance, for up to 500 …


Netherlands suspends AstraZeneca vaccine despite safety assurances

The Netherlands has become the latest country to suspend the use of the Oxford-AstraZeneca vaccine …

Latest content